HeartFlow vs ScreenPoint Transpara

Transpara serves breast screening and HeartFlow serves cardiac CT. HeartFlow's Roadmap Analysis targets consistent CCTA reads across readers, and its Plaque Analysis quantifies plaque. ScreenPoint says Transpara works with whatever mammography systems a site owns, on 2D and 3D mammograms, for single or double reading. The vendor says it was the tool in MASAI, a randomized trial. The Lancet report is independent academic work from Lund University covering more than 105,000 women, and the vendor cites sensitivity of 80.5% against 73.8% for double reading at 98.5% specificity. Transpara has eight 510(k)s on openFDA, the newest decided in August 2026. A screening program or multi-site breast group is the buyer, and the MASAI result comes from a double-reading setting in Swedish screening.